Spanish Español English English

AlzTEST is the new test developed by NEURON to help your physician in the diagnosis of Alzheimer’s disease

Leader in biosolutions for pharmaceutical and agro-food industries

News

    • 21 APR 16
    Neuron Bio and CIEN Foundation to cooperate in the diagnosis of Alzheimer’s disease

    Neuron Bio and CIEN Foundation to cooperate in the diagnosis of Alzheimer’s disease

    Granada 21 April 2016. The Spanish Research Centre Foundation for Neurological Diseases Fundación Centro de Investigación de Enfermedades Neurológicas (CIEN) and Neuron Bio have reached an agreement for the development of joint projects in the field for diagnosis of the Alzheimer’s disease. The framework agreement aims to unite the experience and knowledge of specialists, who

    • 01 APR 16
    Neuron Bio carries out the capital increase with a subscription of 1,021,712 new shares

    Neuron Bio carries out the capital increase with a subscription of 1,021,712 new shares

    As result of the capital increase with pre-emptive subscription rights that ended on 23 March, the number of subscribed shares consists of 1,021,712 shares amounting to € 1,021,712. Consequently, the share capital of Neuron Bio, S.A. amounts to € 9,346,712. Funds raised will be used for the promotion and development of AlzTest®, the aid test

    • 10 MAR 16
    Neuron Bio to extend its patent application for the Alzheimer’s diagnostic aid test to 148 PCT member states

    Neuron Bio to extend its patent application for the Alzheimer’s diagnostic aid test to 148 PCT member states

    Figure. Member states of Patent Cooperation Treaty (PCT) are shown in blue. On 10 March 2016 Neuron Bio (NEU.MC) has extended its European patent application for the Alzheimer’s diagnostic aid test AlzTest®, to 148 contracting states of the Patent Cooperation Treaty (PCT) with file number PCT/EP2016/055090. The content of the international patent application that protects

    • 07 MAR 16
    Neuron Bio, reference laboratory of Merck Millipore

    Neuron Bio, reference laboratory of Merck Millipore

    Granada, 7 March 2016. Neuron Bio has been designated by Merck Millipore as reference laboratory for the Milliplex® immunoassays technology focused on the identification of biomarkers. Neuron Bio uses the Merck Millipore Milliplex® technology since 2011, employed by the company in the creation of AlzTest®, its test to aid in the diagnosis of Alzheimer’s disease.

MAB

  • Neuron Bio is listed on the Alternative Investment Market (MAB) in Spain

    Mercado alternativo bursatil
  • Uso de cookies

    Utilizamos cookies propias y de terceros para realizar análisis de uso y de medición de nuestra web para mejorar nuestros servicios. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.